Cryoport, Inc. (NASDAQ: CYRX) is a Industrials company in the Integrated Freight & Logistics industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | 1.43 | Insider Own | 12.21% | Shs Outstand | 50.40M | Perf Week | 0.20% |
| Market Cap | 762.08M | Forward P/E | - | EPS next Y | -0.65 | Insider Trans | -4.67% | Shs Float | 43.82M | Perf Month | -3.82% |
| Enterprise Value | 724.83M | PEG | 0.11 | EPS next Q | - | Inst Own | - | Short Float | 5.75% | Perf Quarter | 18.50% |
| Income | -36.28M | P/S | 4.09 | EPS this Y | -154.39% | Inst Trans | - | Short Ratio | 3.19 | Perf Half Y | 75.81% |
| Sales | 186.45M | P/B | 1.55 | EPS next Y | 16.14% | ROA | -4.80% | Short Interest | 2.52M | Perf YTD | 57.50% |
| Book/sh | - | P/C | 65.14 | EPS next 5Y | - | ROE | -7.25% | 52W High | 16.80 -10.48% | Perf Year | 72.80% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -7.34% | 52W Low | 7.47 101.33% | Perf 3Y | 0.13% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | -7.59% 17.38% | Gross Margin | 47.08% | Volatility | 4.18% 4.70% | Perf 5Y | -75.50% |
| Dividend TTM | - | EV/Sales | 3.89 | EPS Y/Y TTM | 164.71% | Oper. Margin | -21.25% | ATR (14) | 0.71 | Perf 10Y | 644.83% |
| Dividend Ex-Date | - | Quick Ratio | 1.98 | Sales Y/Y TTM | -21.89% | Profit Margin | -19.45% | RSI (14) | 47.05 | Recom | 2.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.08 | EPS Q/Q | -4.55% | SMA20 | -3.26% | Beta | 1.85 | Target Price | 18.79 |
| Payout | 0.00% | Debt/Eq | 0.47 | Sales Q/Q | 17.07% | SMA50 | -2.44% | Rel Volume | 1.35 | Prev Close | 15.12 |
| Employees | 688 | LT Debt/Eq | 0.08 | Earnings | Nov 03 | SMA200 | 35.32% | Avg Volume | 793.00K | Price | 15.04 |
| IPO Date | Aug 22, 2005 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -6.51% 6.54% | Net Debt/EBITDA | 3.83 | Volume | 1,069,239 | Change | -0.53% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-07-26 | Reiterated | Needham | Buy | $15 → $19 |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $12 → $16 |
| Aug-07-26 | Reiterated | Roth Capital | Buy | $15 → $21 |
| Jul-24-26 | Reiterated | BTIG | Buy | $17 → $25 |
| Jun-08-26 | Reiterated | Jefferies | Hold | $11 → $14 |
| Jun-03-26 | Reiterated | Craig-Hallum | Buy | $20 |
| May-20-26 | Reiterated | Keybanc | Overweight | $52 → $17 |
| May-05-26 | Reiterated | BTIG | Buy | $15 → $17 |
| May-05-26 | Reiterated | Guggenheim | Buy | $11 → $12 |
| May-05-26 | Reiterated | Needham | Buy | $18 → $15 |
Cryoport, Inc. operates as a specialized service provider within the life sciences sector, delivering global temperature-controlled supply chain solutions across the Americas, Europe, the Middle East, Africa, and the Asia Pacific region. Central to their offerings is Cryoportal, a proprietary cloud-based platform designed to streamline the entire logistics process. This robust system facilitates order processing, generates necessary documentation (including customs paperwork), coordinates courier services, offers real-time shipment tracking and monitoring, aids in issue resolution, and ensures adherence to regulatory compliance standards. To guarantee the integrity of sensitive materials during transit, Cryoport provides CryoPort Express Shippers, engineered to maintain the stability of biological commodities throughout their journey. Furthermore, their SmartPak Condition Monitoring System collects vital environmental data, which is then utilized to produce informative dashboards and essential validation reports for each shipment. Their product range also includes specialized containment solutions such as vacuum insulated aluminum dewars and advanced cryogenic freezer systems. Beyond transportation, the company offers extensive biological specimen management services. These encompass cryopreservation storage and ongoing maintenance, meticulous archiving, continuous monitoring, precise tracking, and efficient receipt and delivery of samples. They also manage the transport of frozen biological specimens to and from client facilities and oversee the inbound and outbound flow of these critical materials. Additionally, Cryoport extends its expertise through comprehensive logistics support and management services, alongside short-term consulting in both logistics and engineering. The company primarily caters to the biopharmaceutical, animal health, and human reproductive medicine industries. Founded in 1999, Cryoport's headquarters are situated in Brentwood, Tennessee.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 186 | 176 | 233 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 99 | 93 | 134 | — | — | — | — | — | — | |
| Gross Profit | 88 | 83 | 99 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 110 | 103 | 147 | — | — | — | — | — | — | |
| Research and Development | 18 | 17 | 18 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 0 | 49 | — | — | — | — | — | — | |
| Operating Income | -40 | -37 | -115 | — | — | — | — | — | — | |
| Interest Expense | 3 | 2 | 6 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 11 | 7 | 21 | — | — | — | — | — | — | |
| Net Income Before Taxes | -31 | -32 | -99 | — | — | — | — | — | — | |
| Income Taxes | 2 | 2 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -36 | 78 | -100 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -33 | -34 | -100 | — | — | — | — | — | — | |
| Net Income | -36 | 78 | -100 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.82 | 1.40 | -2.21 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.82 | 1.40 | -2.21 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.82 | 1.40 | -2.21 | — | — | — | — | — | — | |
| EBITDA | -9 | -2 | -66 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | 6.86 | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 4.04 | 2.73 | 1.64 | — | — | — | — | — | — | |
| Gross Margin | 47.31 | 47.16 | 42.49 | — | — | — | — | — | — | |
| Operating Margin | -21.51 | -21.02 | -49.36 | — | — | — | — | — | — | |
| Net Margin | -19.35 | 44.32 | -42.92 | — | — | — | — | — | — | |
| Shares Outstanding | 50 | 50 | 49 | — | — | — | — | — | — | |
| Market Capitalization | 752 | 480 | 381 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | Jun 11 '26 | Sale | 14.47 | 33,600 | 486,239 | 109,719 | Jun 12 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | Jun 11 '26 | Option Exercise | 4.80 | 33,600 | 161,280 | 143,319 | Jun 12 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | Jun 10 '26 | Option Exercise | 4.80 | 1,400 | 6,720 | 111,119 | Jun 12 |
| ZECCHINI EDWARD J | Chief Digital and Tech Officer | Jun 10 '26 | Sale | 15.23 | 1,400 | 21,324 | 109,719 | Jun 12 |
| Mandalam Ramkumar | Director | Jun 08 '26 | Sale | 15.44 | 23,214 | 358,452 | 67,894 | Jun 08 |
| STEFANOVICH ROBERT | Chief Financial Officer | Jun 04 '26 | Sale | 16.27 | 169,427 | 2,756,984 | 109,850 | Jun 08 |
| SHELTON JERRELL | President, CEO | Apr 21 '26 | Option Exercise | 1.87 | 104,007 | 194,493 | 1,230,614 | Apr 23 |
| SHELTON JERRELL | President, CEO | Apr 06 '26 | Option Exercise | 1.87 | 50,000 | 93,500 | 1,126,607 | Apr 08 |
| SHELTON JERRELL | President, CEO | Mar 23 '26 | Sale | 8.18 | 2,894 | 23,673 | 1,051,607 | Mar 25 |
| STEFANOVICH ROBERT | Chief Financial Officer | Mar 23 '26 | Sale | 8.18 | 1,094 | 8,949 | 279,277 | Mar 25 |
| Sawicki Mark W | Chief Scientific Officer | Mar 23 '26 | Sale | 8.18 | 1,341 | 10,969 | 102,356 | Mar 25 |
| SHELTON JERRELL | President, CEO | Mar 23 '26 | Option Exercise | 1.87 | 25,000 | 46,750 | 1,076,607 | Mar 25 |
| SHELTON JERRELL | President, CEO | Mar 16 '26 | Sale | 8.00 | 7,918 | 63,344 | 1,054,501 | Mar 17 |
| ZECCHINI EDWARD J | See Remarks | Mar 16 '26 | Sale | 8.00 | 2,014 | 16,112 | 109,719 | Mar 17 |
| Sawicki Mark W | Chief Scientific Officer | Mar 16 '26 | Sale | 8.00 | 3,235 | 25,880 | 103,697 | Mar 17 |